Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide effect on myocardial fat in T2DM
NCT01951651Phase 4Completed
- Sponsor
- Baylor College of Medicine
- Start
- Apr 2010
- Primary completion
- Oct 2012
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of exenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Baylor College of Medicine. Primary endpoints: Myocardial Fat Content at 6 months and Hepatic Fat Content at 6 months. Started Apr 2010; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01951651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01951651.